We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Robotic Next Generation Sequencing Platform Accurately Screens Thousands of COVID-19 Samples at Once

By LabMedica International staff writers
Posted on 04 Mar 2021
A robotics platform to screen thousands of COVID-19 samples at once has the potential to revolutionize how labs track the spread of viruses and other pathogens, according to new findings.

The study by researchers from the Lunenfeld-Tanenbaum Research Institute (LTRI) at Sinai Health (Toronto, ON, Canada) found that their next-generation, ultra-high-throughput sequencing platform, called C19-SPAR-Se, has a sensitivity rate greater than 95% in positive cases during peak onset. More...
The platform is also cost-effective. The study notes it only costs about USD 8 per test when running thousands of samples at once, as the cost per sample decreases due to economies of scale.

"Identifying positive samples quickly and accurately is critical in beating this pandemic," said Dr. Jeff Wrana, senior investigator at the LTRI and professor in the Department of Molecular Genetics at the University of Toronto. "With new and potentially dangerous variants now circulating, this is a platform that is scalable, automated and capable of analyzing thousands of COVID-19 patient samples in a single instrument run."

Related Links:
Lunenfeld-Tanenbaum Research Institute


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.